Aurobindo Pharma's Bhiwadi Unit Gets OAI Status from US FDA

Introduction

Aurobindo Pharma announced on Tuesday that the United States Food and Drug Administration (US FDA) has classified a manufacturing facility belonging to its wholly-owned subsidiary, Eugia Pharma Specialities Limited, as "Official Action Indicated" (OAI). The classification follows an inspection conducted in late 2025 at the unit located in Bhiwadi, Rajasthan. This development places the facility under increased regulatory scrutiny, although the company has stated it does not anticipate an immediate impact on its business operations.

Details of the FDA Inspection

The US FDA conducted an inspection at Unit-II of Eugia Pharma Specialities, situated in the RIICO Industrial Area in Bhiwadi, Rajasthan. The inspection took place between November 3 and November 14, 2025. At the conclusion of the audit, the regulatory agency issued a Form 483, citing nine specific observations related to operational procedures and compliance. A Form 483 is issued when FDA investigators observe conditions that, in their judgment, may constitute violations of the Food, Drug, and Cosmetic Act and related regulations.

Understanding the 'Official Action Indicated' Status

Following the issuance of the Form 483, the US FDA has now determined the inspection classification for the Bhiwadi unit as OAI. This is the most serious of the three possible classifications, which also include Voluntary Action Indicated (VAI) and No Action Indicated (NAI). An OAI classification signifies that the regulator has found objectionable conditions or practices and believes that regulatory or administrative actions are warranted to address the deficiencies. This can potentially lead to delays in approvals for new products manufactured at the site and may affect market access for existing products if the issues are not resolved satisfactorily.

Company's Response and Market Reaction

In a regulatory filing, Aurobindo Pharma acknowledged the OAI status but sought to reassure stakeholders. The company stated, "At this point in time, the Company doesn’t foresee any impact on the business." It also reiterated its commitment "to maintaining the highest quality manufacturing standards at all of its facilities across the globe." Following the announcement, the company's shares experienced a slight downturn, shedding 0.54% to close at Rs 1,280.50 on the BSE. This indicates a measured but cautious reaction from investors to the regulatory development.

A Pattern of Regulatory Challenges

This is not an isolated incident for Aurobindo Pharma or its subsidiaries. The company has faced a series of regulatory challenges from the US FDA across different facilities, suggesting a broader pattern of compliance issues. In May 2024, the same Bhiwadi Unit-II had received a Form 483 with seven observations, some of which were related to preventing microbial contamination. Furthermore, other units have also come under the FDA's scanner. Eugia Pharma's Unit III in Sangareddy, Telangana, was classified as OAI after an inspection in early 2024. A warehouse operated by Aurobindo Pharma USA Inc. in New Jersey also received an OAI status in May 2024 after an inspection found five observations related to supply chain security.

Summary of Recent FDA Actions

To provide a clearer picture of the recurring regulatory issues, the recent actions by the US FDA against Aurobindo Pharma's facilities are summarized below:

Implications for Future Operations

While Aurobindo Pharma has stated that it does not expect an immediate business impact, the OAI classification for the Bhiwadi unit carries significant long-term implications. The facility will be subject to heightened regulatory oversight, and the company will need to implement comprehensive corrective and preventive actions to address the nine observations to the FDA's satisfaction. Failure to do so could result in warning letters, import alerts, or other enforcement actions. More importantly, the OAI status could delay the approval of new drug applications (ANDAs) filed from this facility, potentially impacting the company's product launch pipeline for the crucial US market.

Investor Outlook

For investors, the repeated instances of FDA scrutiny are a key point of concern. The OAI classification for the Bhiwadi unit, when viewed in conjunction with similar actions at other facilities, raises questions about the robustness of the company's global quality management systems. Investors will be closely monitoring Aurobindo Pharma's disclosures regarding its remediation plan for the Bhiwadi facility and the timeline for its resolution. The effectiveness of the corrective measures and any future communications about a potential re-inspection will be critical in assessing the company's ability to navigate these regulatory hurdles.

Conclusion

Aurobindo Pharma's receipt of an OAI classification for its Eugia Pharma unit in Bhiwadi marks another significant regulatory challenge for the company. While the firm has downplayed any immediate financial impact, the classification highlights ongoing compliance issues that could affect future growth. The company's path forward will depend on its ability to effectively address the FDA's observations and restore the regulator's confidence in its manufacturing practices. Stakeholders will be watching for further updates on the resolution of this matter.